Yaskawa Electric Shares Slide as Weak Profit Overshadows Strong AI Demand 
Arm Stock Falls After HSBC Downgrade, Citing Limited Near-Term AI Upside 
Mastercard Explores Sale of Majority Stake in UK Payments Firm Vocalink: Report 
Samsung to Launch First Yongin Chip Plant by 2029 as South Korea Speeds Up Semiconductor Hub 
SK Hynix Stock Soars as AI Memory Demand Outlook Fuels Chip Rally 
Paramount-Warner Bros. Discovery Merger Faces Lawsuit From 12 States 
Morgan Stanley Names Marks & Spencer Top European Retail Pick, Sees Strong Upside 
Nvidia Tightens AI Chip Sales in Asia With Stricter Customer Approval Process 
Deutsche Bank Fined A$2 Million by ASIC Over OTC Derivatives Reporting Errors 
Genesis Minerals to Acquire Vault in A$5.6 Billion Deal After Regis Withdraws 
Apple Sues OpenAI, Former Employees Over Alleged Trade Secret Theft 
TSMC Q2 Revenue Surges 36% as AI Chip Demand Powers Growth Ahead of Earnings 
BHP Faces Major Port Hedland Strike as Labor Talks Stall Ahead of Production Report 
DBS Targets S$1 Trillion Wealth AUM by 2030 Amid Asia Wealth Boom 
OpenAI Executive Fidji Simo to Step Down Amid Health Challenges Ahead of IPO 
Kitron Q2 Revenue Beats Estimates as Defense Demand Lifts Growth 
Rio Tinto Reports Strong Q2 Iron Ore Sales, Maintains 2026 Production Outlook 
Activist investor Starboard Value has fully exited its position in Pfizer, marking the end of a high-profile effort to pressure the pharmaceutical giant into boosting its flagging share price. According to a recent 13-F regulatory filing, Starboard sold approximately 8.5 million Pfizer shares during the third quarter, unwinding a stake that once totaled 15.4 million shares at the end of Q4 2024.
Starboard initially made waves when it disclosed a roughly $1 billion investment in Pfizer a year ago, stepping in at a time when the company’s stock was trading at roughly half its peak during the pandemic. The fund’s founder, Jeffrey Smith, was outspoken about Pfizer’s performance, arguing at an industry event that the board needed to hold management accountable for persistent underperformance and weak market confidence.
Despite its push for governance and operational improvements, Starboard’s campaign struggled to gain lasting traction. The firm had approached former Pfizer executives—including former CEO Ian Read—for strategic guidance, but discussions reportedly stalled. Pfizer’s current market value sits around $142 billion, a decline from roughly $162 billion when Starboard’s involvement was first revealed in October 2024.
Starboard, known for its aggressive activist strategies, has been active across several industries this year, taking positions in companies such as TripAdvisor, Rogers, and BILL Holdings, where it secured a board seat shortly after investing. However, its Pfizer exit marks a notable retreat from what was once one of its most closely watched campaigns.
The same filing also revealed that Starboard fully divested from Fortrea Holdings, a contract research organization spun off from LabCorp in 2023. The hedge fund sold 2.5 million Fortrea shares during the third quarter. Since Starboard disclosed its investment in October 2023, Fortrea’s share price has fallen nearly 50%, adding another setback to the fund’s recent positions.
Starboard declined to comment on the latest disclosures.
